[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://www.lyell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 300, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 72, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 82734, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 65, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1021376, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 750442, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Lang J.D.", "age": 48, "title": "Advisor", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 1129132, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 63, "title": "Founder & Scientific Advisor", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles W. Newton", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 744737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Lee Ph.D.", "age": 47, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen  Rose", "title": "Senior Vice President of Communications & Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.65, "open": 10.65, "dayLow": 10.5, "dayHigh": 10.94, "regularMarketPreviousClose": 10.65, "regularMarketOpen": 10.65, "regularMarketDayLow": 10.5, "regularMarketDayHigh": 10.94, "payoutRatio": 0.0, "beta": -0.198, "forwardPE": -12.809525, "volume": 21635, "regularMarketVolume": 21635, "averageVolume": 143583, "averageVolume10days": 31600, "averageDailyVolume10Day": 31600, "bid": 7.71, "ask": 13.63, "bidSize": 2, "askSize": 2, "marketCap": 206712512, "fiftyTwoWeekLow": 7.65, "fiftyTwoWeekHigh": 32.1, "priceToSalesTrailing12Months": 3445.2085, "fiftyDayAverage": 10.2988, "twoHundredDayAverage": 12.1821, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -14970466, "profitMargins": 0.0, "floatShares": 12068093, "sharesOutstanding": 19211200, "sharesShort": 188200, "sharesShortPriorMonth": 260638, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0098, "heldPercentInsiders": 0.20287001, "heldPercentInstitutions": 0.50014, "shortRatio": 2.57, "shortPercentOfFloat": 0.012, "impliedSharesOutstanding": 19211200, "bookValue": 20.155, "priceToBook": 0.53386253, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -331396992, "trailingEps": -24.26, "forwardEps": -0.84, "lastSplitFactor": "1:20", "lastSplitDate": 1748822400, "enterpriseToRevenue": -249.508, "enterpriseToEbitda": 0.077, "52WeekChange": -0.6616352, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 10.76, "targetHighPrice": 12.0, "targetLowPrice": 10.0, "targetMeanPrice": 11.0, "targetMedianPrice": 11.0, "recommendationMean": 3.5, "recommendationKey": "hold", "numberOfAnalystOpinions": 2, "totalCash": 276790016, "totalCashPerShare": 14.408, "ebitda": -194868000, "totalDebt": 55107000, "quickRatio": 7.5, "currentRatio": 7.647, "totalRevenue": 60000, "debtToEquity": 18.435, "revenuePerShare": 0.004, "returnOnAssets": -0.25388, "returnOnEquity": -0.76585996, "grossProfits": 60000, "freeCashflow": -81777752, "operatingCashflow": -171480000, "revenueGrowth": -0.385, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -5412.125, "financialCurrency": "USD", "symbol": "LYEL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623936600000, "postMarketChangePercent": 0.0, "postMarketPrice": 10.76, "postMarketChange": 0.0, "regularMarketChange": 0.110001, "regularMarketDayRange": "10.5 - 10.94", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 143583, "fiftyTwoWeekLowChange": 3.1100001, "fiftyTwoWeekLowChangePercent": 0.40653595, "fiftyTwoWeekRange": "7.65 - 32.1", "fiftyTwoWeekHighChange": -21.339998, "fiftyTwoWeekHighChangePercent": -0.6647975, "fiftyTwoWeekChangePercent": -66.16352, "regularMarketChangePercent": 1.03287, "regularMarketPrice": 10.76, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1755893404, "regularMarketTime": 1755892801, "exchange": "NMS", "messageBoardId": "finmb_590661061", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "earningsTimestampStart": 1763064000, "earningsTimestampEnd": 1763064000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -24.26, "epsForward": -0.84, "fiftyDayAverageChange": 0.46119976, "fiftyDayAverageChangePercent": 0.04478189, "twoHundredDayAverageChange": -1.4221001, "twoHundredDayAverageChangePercent": -0.11673685, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-17", "averageAnalystRating": "3.5 - Hold", "cryptoTradeable": false, "displayName": "Lyell Immunopharma", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]